Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

News Releases

Nov 05, 2026
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Guggenheim 3 rd Annual Healthcare Conference on Tuesday, November 10 th, where management plans to participate
Nov 03, 2026
Tarsus Reports Third Quarter 2026 Financial Results
Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch Appointed Neera Clase as Chief Commercial Officer Management
Oct 28, 2026
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served as Tarsus’ Interim Chief Commercial Officer since July 2026 and previously
Sep 01, 2026
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21 st Annual Healthcare Conference on Tuesday, September 8 th H.C.
Displaying 1 - 10 of 24